NEW YORK, November 22, 2026 — The U.S. Food and Drug Administration issued a Complete Response Letter on Nov. 21, declining to approve deramiocel, an allogeneic cardiosphere‑derived cell therapy from Capricor Therapeutics, for Duchenne muscular dystrophy (DMD). The agency said the clinical evidence did not meet the standards for approval and highlighted serious deficiencies in the Phase 3 HOPE‑3 trial.
Regulatory Decision and Its Context
The FDA’s second Complete Response Letter cited “insufficient evidence of effectiveness” and “additional undisclosed clinical deficiencies” in the data package submitted by Capricor. This follows an earlier CRL in July 2025 and an advisory committee vote of 9–3 against approval for the cardiomyopathy indication in July 2026. Capricor had resubmitted a major amendment to its Biologics License Application, adding open‑label extension data and shifting the proposed label to focus on upper‑limb function.
Why the Data Were Deemed Insufficient
Reviewers disputed whether the HOPE‑3 trial met its original statistical analysis plan, despite the study meeting its prespecified primary endpoint. The trial enrolled 106 advanced DMD patients and reported a 4.55 % least‑squares mean advantage in the Performance of the Upper Limb version 2.0 (PUL2.0) change at 12 months. However, the FDA concluded that the dataset did not reach the threshold for substantial evidence of effectiveness and noted other clinical deficiencies that were not disclosed by the company.
Details of the HOPE‑3 Trial
HOPE‑3 randomly assigned participants aged 10 years and older with advanced DMD to receive deramiocel (150 million cells intravenously every three months for four doses) or placebo. All were on stable corticosteroids, and more than 75 % had a clinical diagnosis of cardiomyopathy. The trial showed a 4.55 % advantage in total PUL2.0 score change at 12 months (95 % CI, 0.47 to 8.63; P = .029). A key secondary endpoint indicated a 91 % slowing of left ventricular ejection‑fraction decline, though confidence intervals were not published. Earlier, two randomized, double‑blind, placebo‑controlled trials (HOPE‑2 and HOPE‑3) failed to demonstrate that deramiocel could stave off heart failure or preserve arm muscle function.
Implications for Patients and Capricor
For the Duchenne community, the decision represents a setback after years of anticipation. The Muscular Dystrophy Association expressed empathy for families while emphasizing the need for reliable clinical evidence. Capricor’s CEO Linda Marbán said the company is evaluating next steps, noting that the therapy remains investigational. The stock rose 5 % ahead of the decision but is projected to fall 17 % for the week following the rejection.
Next Steps for the Company and the Regulatory Pathway
Capricor may consider additional studies to address the FDA’s concerns or pursue alternative regulatory strategies. The company continues to advance launch preparations and is managing an arbitration with Nippon Shinyaku’s unit NS Pharma, which it says will not delay patient access if approval is eventually granted.
Patients and families interested in emerging DMD therapies should stay informed about ongoing trials and discuss options with their healthcare providers.
Sources
- Statement from the Muscular Dystrophy Association on the FDA Decision Not to Approve Deramiocel for Duchenne Muscular Dystrophy | Muscular Dystrophy Association
- Eduardo Marbán
- FDA rejects Capricor Therapeutics' Duchenne therapy, a decision that was a long time coming
- FDA Issues Second Complete Response Letter for Deramiocel in Duchenne Muscular Dystrophy | NeurologyLive – Clinical Neurology News and Neurology Expert Insights
- CAPR Stock Gains Ahead Of Weekend FDA Deramiocel Decision After Rough Week
- Key facts: FDA Extends Deramiocel Review; Capricor Reports Q3 Loss
Photo: CaptJayRuffins (CC BY-SA 4.0)





